Hepatic Artery Transfusion of NKG2D CAR-NK Cells Followed by Intravenous Infusion of NKG2D CAR-T Cells to Treat Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments: a Phase I Exploratory Clinical Trial

This is a single-center, single-arm, open-label, dose-escalation clinical study to evaluate the safety and preliminary efficacy of NKG2D CAR-NK cells followed by NKG2D CAR-T cells in patients with advanced solid tumors (e.g.,colorectal cancer) with liver metastases who have failed standard treatments. The study primarily focuses on determining the maximum tolerated dose and recommended phase II dose through sequential cohort dose escalation, while secondarily characterizing the pharmacokinetic parameters and collecting initial efficacy data regarding tumor response. This investigation compre

Trial Details

NCT ID
NCT07021534
Phase
PHASE1
Sponsor
Zhejiang University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • NKG2D CAR NK and NKG2D CAR T cells
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Age between 18 and 75 years (inclusive of boundary values), both males and females are eligible.
  • Advanced solid tumors with liver metastasis that have failed prior standard treatment (including disease progression and intolerable adverse reacti…
  • Patients with high expression of NKG2D ligands in tumor tissue sections will be prioritized for enrollment.
  • The expected survival of the subjects is ≥12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →